- Home
- DRUG vs LXRX Comparison
DRUG vs LXRX Comparison
Compare DRUG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- LXRX
- Stock Information
- Founded
- DRUG 2019
- LXRX 1995
- Country
- DRUG United States
- LXRX United States
- Employees
- DRUG N/A
- LXRX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- LXRX Health Care
- Exchange
- DRUG Nasdaq
- LXRX Nasdaq
- Market Cap
- DRUG 484.7M
- LXRX 552.4M
- IPO Year
- DRUG N/A
- LXRX 2000
- Fundamental
- Price
- DRUG $69.38
- LXRX $1.45
- Analyst Decision
- DRUG Strong Buy
- LXRX Buy
- Analyst Count
- DRUG 9
- LXRX 5
- Target Price
- DRUG $81.67
- LXRX $3.23
- AVG Volume (30 Days)
- DRUG 108.7K
- LXRX 2.9M
- Earning Date
- DRUG 08-11-2025
- LXRX 11-11-2025
- Dividend Yield
- DRUG N/A
- LXRX N/A
- EPS Growth
- DRUG N/A
- LXRX N/A
- EPS
- DRUG N/A
- LXRX N/A
- Revenue
- DRUG N/A
- LXRX $58,432,000.00
- Revenue This Year
- DRUG N/A
- LXRX $66.55
- Revenue Next Year
- DRUG N/A
- LXRX N/A
- P/E Ratio
- DRUG N/A
- LXRX N/A
- Revenue Growth
- DRUG N/A
- LXRX 1504.83
- 52 Week Low
- DRUG $23.18
- LXRX $0.28
- 52 Week High
- DRUG $70.23
- LXRX $2.08
- Technical
- Relative Strength Index (RSI)
- DRUG 68.34
- LXRX 53.83
- Support Level
- DRUG $62.21
- LXRX $1.39
- Resistance Level
- DRUG $70.23
- LXRX $1.58
- Average True Range (ATR)
- DRUG 6.00
- LXRX 0.11
- MACD
- DRUG 0.52
- LXRX -0.01
- Stochastic Oscillator
- DRUG 96.01
- LXRX 31.11
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.